Lumexa Imaging (NASDAQ:LMRI) Announces FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.860-0.900 for the period, compared to the consensus estimate of 0.660. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analyst Ratings Changes

A number of research firms recently issued reports on LMRI. Wall Street Zen upgraded shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday, September 22nd. Barclays raised their price target on shares of Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Lumexa Imaging in a research note on Thursday, August 13th. Finally, UBS Group reiterated a “strong-buy” rating on shares of Lumexa Imaging in a report on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $16.40.

Lumexa Imaging Stock Up 14.2%

NASDAQ:LMRI traded up $1.98 on Wednesday, hitting $15.90. The stock had a trading volume of 143,063 shares, compared to its average volume of 676,337. The business’s fifty day moving average is $11.24 and its 200 day moving average is $11.07. The company has a market cap of $1.53 billion and a PE ratio of -32.44. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a 52 week low of $6.45 and a 52 week high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last released its quarterly earnings data on Tuesday, November 10th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.07 by $0.19. The firm had revenue of $271.97 million for the quarter. On average, equities research analysts expect that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Latest Lumexa Imaging News

Here’s some of the latest news about LMRI:

• Positive Sentiment: Several reports described Q3 EPS as beating expectations: one cited $0.26 per share versus a $0.07 consensus, while another reported a 4-cent beat. An earnings article also highlighted interest costs being cut roughly in half, which may have helped earnings. StreetInsider Q3 results Q3 earnings and interest costs
• Positive Sentiment: Revenue increased 5% year over year to about $272 million, gross profit rose 16.9%, and operating cash flow climbed to $34.8 million from a year earlier. These trends point to improved revenue and cash generation. Q3 financial details
• Neutral Sentiment: LMRI also provided guidance, but the supplied reports do not specify its details, limiting assessment of the outlook. Guidance report

Lumexa Imaging Company Profile

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.